Nateglinide and Concomitant disease progression - a phase IV clinical study of FDA data

Summary:

Concomitant disease progression is reported as a side effect among people who take Nateglinide (nateglinide), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Valsartan, and have High blood pressure.

The phase IV clinical study analyzes which people have Concomitant disease progression when taking Nateglinide. It is created by eHealthMe based on reports of 1,756 people who have side effects when taking Nateglinide from the FDA, and is updated regularly.

What is Nateglinide?

Nateglinide has active ingredients of nateglinide. It is often used in type 2 diabetes. eHealthMe is studying from 1,771 Nateglinide users. Check the latest studies of Nateglinide.

What is Concomitant disease progression?

Concomitant disease progression (progress in accompanying disease) is found to be associated with 372 drugs and 622 conditions by eHealthMe. Check the latest studies of Concomitant disease progression.

On Jul, 27, 2026

1,756 people reported to have side effects when taking Nateglinide.
Among them, 15 people (0.85%) have Concomitant disease progression.

Could Nateglinide cause Concomitant disease progression?

Among these 15 people:

How long have people been on Nateglinide when they have Concomitant disease progression? *

What is the gender of people who have Concomitant disease progression when taking Nateglinide? *

female: 6.67 %
male: 93.33 %

What is the age of people who have Concomitant disease progression when taking Nateglinide? *

What are other drugs people take besides Nateglinide? *

Valsartan: 14 people, 93.33%
Amlodipine: 13 people, 86.67%

What are other side effects people have besides Concomitant disease progression? *

Weakness: 14 people, 93.33%
Chest Pain: 14 people, 93.33%
High Blood Pressure: 13 people, 86.67%
Angiodysplasia (small vascular malformation of the gut): 13 people, 86.67%
Arteriovenous Malformation: 13 people, 86.67%
Colonic Polyp (extra part of colon tissue grow in intestine): 13 people, 86.67%
Diverticulum Intestinal (a pouch that is attached to the first part of the small intestine): 13 people, 86.67%
Faeces Discolored: 13 people, 86.67%
Gastritis (inflammation of stomach): 13 people, 86.67%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 13 people, 86.67%

What are the existing conditions these people have? *

High Blood Pressure: 13 people, 86.67%
Glucose Tolerance Impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Nateglinide and have Concomitant disease progression?

- Check whether Concomitant disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nateglinide:

Nateglinide (1,771 reports)

Browse all side effects of Nateglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Concomitant disease progression:

Concomitant disease progression (372 drugs)

Browse all the conditions that are associated with Concomitant disease progression:

Concomitant disease progression (622 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nateglinide (the active ingredients of Nateglinide) and Nateglinide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.